Persistent HPV infections are now recognized as the cause of essentially all cervical cancers, as well as most cases of anal cancer. In 2011, more than 12,000 women in the United States are expected to be diagnosed with cervical cancer and more than 4,000 are expected to die from it. Cervical cancer is diagnosed in nearly half a million women each year worldwide, claiming a quarter of a million lives annually.
Globally, HPV is the most common sexually transmitted infection. Like all sexually transmitted infections, peak prevalence of HPV infection occurs within the first decade after sexual debut, typically between the ages of 15 to 25 years in most western countries.
Persistent viral infection with carcinogenic HPV genotypes causes virtually all cancer of the cervix. Carcinogenic HPV infections also cause most cancers of the anus, vagina, vulva, penis, and about a third to a half of the cancers the oropharynx.
In 10 to 20 percent of people, however, the infection persists (this does not mean mutation). In this situation, there is a greater chance of developing cervical pre-cancer and then cancer. However, it usually takes at least 20 years for HPV infection to cause cervical cancer. Thus, regular testing is important in detecting cervical abnormalities early, before cancer develops.
Over 100 different types of HPV have been identified; 40 of these are known to infect the cervix and 15 are known to cause cervical cancer. Researchers have labeled the HPV types as being high or low risk for causing cervical cancer.
HPV types 6 and 11 can cause about 90 percent of genital warts. These types are low-risk because they do not cause cervical cancer.
Types 16 and 18 are the high-risk types that cause most (about 70 percent) cases of cervical cancer. HPV types 45 and 31 are also high-risk types, causing about 5 to 10 percent of cervical cancers.
There is no curative treatment for HPV, if the body is unable to fight is off (as with 10-20% of cases) the treatment is based on control of mutated cells through laser therapy surgical removal and if needed other cancer therapies
(Gardasil®) helps to prevent infection with four HPV types (6, 11, 16, and 18) (efficacy 95-100%)
The other vaccine (Cervarix®) prevents infection with HPV types 16 and 18, (efficacy 95-100) and it may offer some protection against HPV types 45 and 31. (60-75%)